Brokerages Set MEDNAX Inc (MD) Target Price at $50.62

Shares of MEDNAX Inc (NYSE:MD) have been assigned a consensus recommendation of “Hold” from the seventeen ratings firms that are presently covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a sell rating, ten have given a hold rating and four have issued a buy rating on the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $50.62.

MD has been the subject of several recent analyst reports. Robert W. Baird dropped their price objective on shares of MEDNAX from $48.00 to $40.00 and set a “neutral” rating for the company in a report on Friday, November 2nd. Credit Suisse Group dropped their price objective on shares of MEDNAX from $55.00 to $50.00 and set an “outperform” rating for the company in a report on Tuesday, November 6th. BMO Capital Markets lowered their price target on shares of MEDNAX from $48.00 to $43.00 and set a “market perform” rating for the company in a report on Friday, November 2nd. UBS Group assumed coverage on shares of MEDNAX in a report on Friday, November 16th. They issued a “sell” rating and a $37.00 price target for the company. Finally, ValuEngine lowered shares of MEDNAX from a “sell” rating to a “strong sell” rating in a report on Thursday, November 1st.

NYSE MD opened at $40.20 on Thursday. The company has a market cap of $3.59 billion, a PE ratio of 11.52, a PEG ratio of 1.07 and a beta of 0.33. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.43 and a quick ratio of 1.43. MEDNAX has a 1-year low of $37.26 and a 1-year high of $63.04.

MEDNAX (NYSE:MD) last posted its quarterly earnings data on Thursday, November 1st. The company reported $0.94 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.97 by ($0.03). The firm had revenue of $896.60 million for the quarter, compared to analyst estimates of $908.15 million. MEDNAX had a return on equity of 10.45% and a net margin of 9.50%. The business’s quarterly revenue was up 3.2% on a year-over-year basis. During the same period in the previous year, the business posted $0.87 EPS. Equities analysts predict that MEDNAX will post 3.57 earnings per share for the current year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Point72 Hong Kong Ltd bought a new position in shares of MEDNAX during the second quarter worth $172,000. Ardevora Asset Management LLP bought a new position in shares of MEDNAX during the third quarter worth $9,892,000. GHP Investment Advisors Inc. boosted its position in shares of MEDNAX by 19.8% during the third quarter. GHP Investment Advisors Inc. now owns 9,775 shares of the company’s stock worth $456,000 after purchasing an additional 1,615 shares in the last quarter. Eagle Boston Investment Management Inc. boosted its position in shares of MEDNAX by 5.2% during the third quarter. Eagle Boston Investment Management Inc. now owns 257,103 shares of the company’s stock worth $11,996,000 after purchasing an additional 12,595 shares in the last quarter. Finally, Oakbrook Investments LLC boosted its position in shares of MEDNAX by 33.3% during the third quarter. Oakbrook Investments LLC now owns 11,600 shares of the company’s stock worth $541,000 after purchasing an additional 2,900 shares in the last quarter. 98.51% of the stock is owned by hedge funds and other institutional investors.

MEDNAX Company Profile

MEDNAX, Inc, together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology, pediatric cardiology, and other pediatric subspecialties physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care; and acute and chronic pain management services.

Featured Story: What Is An Exchange-Traded Fund (ETF)?

Analyst Recommendations for MEDNAX (NYSE:MD)

Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit